β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease
- 31 July 2002
- Vol. 23 (7) , 1205-1214
- https://doi.org/10.1016/s0196-9781(02)00056-6
Abstract
No abstract availableKeywords
This publication has 89 references indexed in Scilit:
- Evaluation of CSF-tau and CSF-Aβ42 as Diagnostic Markers for Alzheimer Disease in Clinical PracticeArchives of Neurology, 2001
- Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairmentNeuroscience Letters, 1999
- Genetic testing for Alzheimerʼs disease: how close is reality?Current Opinion in Psychiatry, 1999
- Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer DiseaseArchives of Neurology, 1999
- Unusual phenotypic alteration of β amyloid precursor protein (βAPP) maturation by a new Val-715 → Met βAPP-770 mutation responsible for probable early-onset Alzheimer’s diseaseProceedings of the National Academy of Sciences, 1999
- Evidence That Tumor Necrosis Factor α Converting Enzyme Is Involved in Regulated α-Secretase Cleavage of the Alzheimer Amyloid Protein PrecursorJournal of Biological Chemistry, 1998
- Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”Neurobiology of Aging, 1998
- Serpents on the road to dementia and deathNature Medicine, 1997
- Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein geneNature, 1991
- A4 amyloid protein deposition and the diagnosis of Alzheimer's diseaseNeurology, 1988